These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34569060)

  • 1. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
    Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
    Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
    Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
    Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
    [No Abstract]   [Full Text] [Related]  

  • 3. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
    Boot A; Jiang N; Rozen SG
    Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    Dickman KG; Chen CH; Grollman AP; Pu YS
    World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy.
    Shan H; Tian W; Hong Y; Xu B; Wang C; Yu B; Wang X
    BMC Complement Med Ther; 2020 Jun; 20(1):166. PubMed ID: 32493345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive Effects of Arsenic and Aristolochic Acid in Chemical Carcinogenesis of Upper Urinary Tract Urothelium.
    Chen CH; Grollman AP; Huang CY; Shun CT; Sidorenko VS; Hashimoto K; Moriya M; Turesky RJ; Yun BH; Tsai K; Wu S; Chuang PY; Tang CH; Yang WH; Tzai TS; Tsai YS; Dickman KG; Pu YS
    Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):317-325. PubMed ID: 33277322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
    Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
    Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Characterization of Microrna Interference and Aristolochic Acid Intoxication Found in Upper Tract Urothelial Carcinoma in Patients with Balkan Endemic Nephropathy: A Systematic Review of the Current Literature.
    Bašić D; Ignjatović I; Janković Veličković L; Veljković A
    Balkan J Med Genet; 2023 May; 25(2):105-111. PubMed ID: 37265966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
    Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
    Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
    Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
    Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.
    Kang YC; Chen MH; Lin CY; Lin CY; Chen YT
    Ther Adv Drug Saf; 2021; 12():2042098621997727. PubMed ID: 33815744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular aspects of upper tract urothelial carcinoma.
    Patel N; Arya M; Muneer A; Powles T; Sullivan M; Hines J; Kelly J
    Urol Oncol; 2014 Jan; 32(1):28.e11-20. PubMed ID: 23428541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
    Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
    Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
    Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
    Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
    Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
    Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latency period of aristolochic acid-induced upper urinary tract urothelial carcinoma.
    Jhuang JR; Chiu PC; Hsieh TC; Chen CH; Pu YS; Lee WC
    Front Public Health; 2023; 11():1072864. PubMed ID: 36969664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up.
    Lemy A; Wissing KM; Rorive S; Zlotta A; Roumeguere T; Muniz Martinez MC; Decaestecker C; Salmon I; Abramowicz D; Vanherweghem JL; Nortier J
    Am J Kidney Dis; 2008 Mar; 51(3):471-7. PubMed ID: 18295063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid.
    Jelaković B; Dika Ž; Arlt VM; Stiborova M; Pavlović NM; Nikolić J; Colet JM; Vanherweghem JL; Nortier JL
    Semin Nephrol; 2019 May; 39(3):284-296. PubMed ID: 31054628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy.
    Ahn B; Kim D; Park KJ; Park JM; Yoon SY; Hong B; Cho YM; Kim D
    Cancer Res Treat; 2024 Jul; 56(3):856-870. PubMed ID: 38147818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.